Drug Trial Radar · NCT01341782
Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism
Last checked: Nov 19, 2026Latest source record: Jun 6, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
255
Actual
Start
May 2011
Primary completion
Apr 2012
Study completion Apr 2012
Sponsor
- Lead sponsor
- AbbVie (prior sponsor, Abbott)AbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Apr 26, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a comparison of the efficacy and safety of paricalcitol injection with maxacalcitol injection in adult Japanese chronic kidney disease patients receiving hemodialysis with secondary hyperparathyroidism. The main objective of this study is to demonstrate the efficacy of paricalcitol injection in reducing levels of parathyroid hormone without clinically significant hypercalcemia, compared to maxacalcitol injection.
Conditions
- Secondary Hyperparathyroidism
- Hemodialysis
Interventions
paricalcitolDrug
maxacalcitolDrug
paricalcitol placeboDrug
maxacalcitol placeboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Target Intact Parathyroid Hormone (iPTH) and Without HypercalcemiaTime frame: iPTH measured during the last three weeks of treatment (Weeks 11, 12, and 13). Calcium measured throughout the study (Weeks 1-13).
Locations
45 sites in 1 country. Site status is shown where the registry gives one.
Site Reference ID/Investigator# 53485
Aichi, Japan
Site Reference ID/Investigator# 51571
Chiba, Japan
Site Reference ID/Investigator# 52963
Chiba, Japan
Site Reference ID/Investigator# 52966
Chiba, Japan
Site Reference ID/Investigator# 51578
Gifu, Japan
Site Reference ID/Investigator# 52965
Gunma, Japan
Site Reference ID/Investigator# 53782
Hadano, Japan
Site Reference ID/Investigator# 57483
Himeji, Japan
Site Reference ID/Investigator# 57487
Hokkaido, Japan
Site Reference ID/Investigator# 53484
Hyōgo, Japan
Site Reference ID/Investigator# 54385
Ibaraki, Japan
Site Reference ID/Investigator# 51581
Kagawa, Japan
Site Reference ID/Investigator# 59164
Kagoshima, Japan
Site Reference ID/Investigator# 51574
Kanagawa, Japan
Site Reference ID/Investigator# 51575
Kanagawa, Japan
Site Reference ID/Investigator# 52751
Kodaira, Japan
Site Reference ID/Investigator# 62025
Koga, Japan
Site Reference ID/Investigator# 54384
Matsumoto, Japan
Site Reference ID/Investigator# 52745
Midori, Japan
Site Reference ID/Investigator# 51569
Mito, Japan
Site Reference ID/Investigator# 52964
Nagano, Japan
Site Reference ID/Investigator# 53483
Nagano, Japan
Site Reference ID/Investigator# 51582
Nagasaki, Japan
Site Reference ID/Investigator# 54388
Nagoya, Japan
Site Reference ID/Investigator# 51576
Niigata, Japan
Site Reference ID/Investigator# 51577
Niigata, Japan
Site Reference ID/Investigator# 51580
Osaka, Japan
Site Reference ID/Investigator# 52747
Osaka, Japan
Site Reference ID/Investigator# 52748
Osaka, Japan
Site Reference ID/Investigator# 52750
Osaka, Japan
Site Reference ID/Investigator# 51570
Saitama, Japan
Site Reference ID/Investigator# 54387
Sakai, Japan
Site Reference ID/Investigator# 52746
Sapporo, Japan
Site Reference ID/Investigator# 51579
Shizuoka, Japan
Site Reference ID/Investigator# 62024
Takasaki, Japan
Site Reference ID/Investigator# 51572
Tokyo, Japan
Site Reference ID/Investigator# 52752
Tokyo, Japan
Site Reference ID/Investigator# 53482
Tokyo, Japan
Site Reference ID/Investigator# 59162
Tokyo, Japan
Site Reference ID/Investigator# 59966
Tokyo, Japan
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.